NEW YORK (GenomeWeb News) – Life Technologies said today that it has formed a translational research collaboration with the University of Cambridge that will enable researchers to use the firm’s sequencing technologies through the Eastern Sequence and Informatics Hub at Addenbrooke’s Hospital in Cambridge.
Under the collaboration, European researchers studying cancer, diabetes, and other disorders will be able to use three SOLiD 3 Plus Systems for next generation targeted resequencing and whole transcriptome analysis studies.
The sequencing hub at Cambridge was funded by the UK’s Medical Research Council, the National Institute for Health Research, and the University’s Clinical School. Its mission is to help scientists use genetic information to develop new treatments, diagnostics, and prevention strategies for major diseases.
Cambridge Professor John Todd said in a statement that the sequencing tools will provide researchers with “the throughput and accuracy required for comprehensive characterization of disease programs.
“The translation of this information into clinically relevant knowledge will have a direct impact on the treatment of human disease through the development of better diagnostic, prognostic, and therapeutic agents," Todd added.